A recent press release from the National Institutes of Health calls attention to a study, published in Stem Cell Reports, that researchers have “developed a clinical-grade stem cell line, which has the potential to accelerate the advance of new medical applications and cell-based therapies for millions of people suffering from such ailments as Alzheimer’s disease, Parkinson’s disease, spinal cord injury, diabetes, and muscular dystrophy.”  The development of these clinical grade stem cells, the release notes, “removes a significant barrier in the development of cell-based therapies.”  But is NIH’s promotion of “stem cells” anything new?

View More